The annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of Leqembi for approval, looks “more realistic” than previous guidance, according to Jefferies ...

The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.

The parent of Novo Nordisk is acquiring 60% ownership of Single Use Support. Elsewhere, ICER is raising questions about a PTSD drug and BioMarin is cut jobs after a pipeline review.

Uniquity Bio emerged from stealth mode ready to begin Phase 2 trials of an antibody targeting the protein TSLP in asthma and COPD.

The firm, one of the sector’s more active crossover investors, closed the fund during a surge in the financings that bridge biotechs to the public markets.

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

The reduction of 1,500 roles in the first quarter is part of CEO Bill Anderson’s plan to shrink Bayer’s bureaucracy and “radically realign” its culture.

The firm, which closed a $167 million fund, aims to fill a “crucial gap” by growing the companies startups turn to for outsourced services, founder Todd Holmes told BioPharma Dive.

The biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based radiopharmaceutical technology in one of the industry’s hottest fields.

Through collaborative efforts with medical professionals, researchers, and pharmaceutical companies, the Foundation strives ...

The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.” ...

Comorbidities can impact how a participant responds to a treatment, exacerbate side effects or interact with investigational drugs, which could lead to adverse events or alter the effectiveness of ...